Racura Oncology Ltd
RAC
Company Profile
Business description
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUST: +61 280513043
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
Stocks News & Analysis
stocks
Big 4 earnings: Morningstar analysts form view on impact of slowing housing market
Big 4 bank maintains Fair Value, Short-term earnings not material enough to shift valuation for key player
stocks
ASX healthcare share remains cheap despite mixed earnings result
Shares in Aussie listed healthcare name undervalued post earnings.
stocks
Wide moat ASX share beats earnings guidance
Wide moat share continues to grow despite a challenging residential construction market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,443.70 | 17.90 | 0.19% |
| CAC 40 | 8,714.94 | 11.09 | -0.13% |
| DAX 40 | 26,391.42 | 67.54 | 0.26% |
| Dow JONES (US) | 53,791.85 | 184.13 | -0.34% |
| FTSE 100 | 10,844.19 | 18.31 | -0.17% |
| HKSE | 25,652.82 | 284.67 | -1.10% |
| NASDAQ | 26,445.45 | 159.91 | -0.60% |
| Nikkei 225 | 66,970.22 | 1,363.51 | 2.08% |
| NZX 50 Index | 13,860.66 | 27.58 | -0.20% |
| S&P 500 | 7,728.20 | 24.91 | -0.32% |
| S&P/ASX 200 | 9,250.60 | 13.80 | 0.15% |
| SSE Composite Index | 3,934.09 | 32.50 | -0.82% |